The global leader's innovative regenerative medical technology and devices vastly improve patient outcomes and reduce overall medical costs. SINGAPORE, Nov. 8, 2022 /PRNewswire/ Osteopore International (ASX:OSX) ("Osteopore", "OSX" or the "Company"), a Singapore- and Australia-based med-tech company focusing on facilitating natural tissue regeneration, is primed for the global limelight after quietly developing and commercialising its novel 3D-printed bioresorbable scaffold implants that have the potential to revolutionise the way surgeons help patients to naturally regrow bones and other tissues. Left to Right: Mark Leong, Executive Chairman of Osteopore, Goh Khoon Seng, CEO of Osteopore and Lim Jing, COO & CTO of Osteopore Osteopore leverages technology that has been researched and developed in Singapore and its patent-protected 3D-printed scaffold implants use a bioresorbable material to mimic the complex and inter-connected microstructure of b
Singapore invents fully bioresorbable facial bone fixation solution
Singapore invents fully bioresorbable facial bone fixation solution 11 December 2020 | News
Photo Credit: Osteopore International and Magloy Tech
Singapore-based
Osteopore International, announces their partnership with National University of Singapore (NUS) startup,
Magloy Tech, to commercialise a first-of-its-kind fully degradable facial bone fixation solution consisting of dissolvable magnesium plates and screws.
Currently, Osteopore specialises in the 3D printing of bioresorbable polymer bone implants, which dissolve into carbon dioxide and water in the body within 18 - 24 months. This new solution in collaboration with Magloy Tech will further help facilitate the natural healing for bone fractures, defects and leave zero residue after the wound is restored. It will also significantly reduce post-surgery complication rates and eliminate revision surgeries that are typically associated with permanent